Table 3.
Summary of studies reporting impact of ADAs on safety/efficacy
| Author | Drug | Impact on | ||
| Efficacy | Safety | PK | ||
| Agrawal et al (2017)20 | Nivolumab | |||
| Antonia et al (2016)21 | Durvalumab+tremelimumab | NA | ||
| Fukudo et al (2019)26 | Nivolumab or pembrolizumab | NA | ||
| Hellman et al (2021)31 | LY3415244 | NA | ||
| Johnson et al (2019)34 | Sasanlimab | NA | ||
| Kelley et al (2021)35 | Tremelimumab+durvalumab | NA | ||
| Kverneland et al (2018)38 | Ipilimumab | NA | ||
| Lu et al (2021)40 | Dostarlimab | |||
| Ma et al (2021)41 | Ipilimumab | NA | NA | |
| Patnaik et al (2021)52 | Lodapolimab | NA | NA | |
| Peters et al (2022)44 | Atezolizumab | NA | ||
| Sasson et al (2021)45 | Pembrolizumab | NA | ||
| Shemesh et al (2019)46 | Atezolizumab | NA | ||
| van Vugt et al (2019)48 | Pembrolizumab | |||
| Wang et al (2019)97 | Sintilimab | NA | NA | |
| Wilkins et al (2019)49 | Avelumab | NA | NA | |
| Wu et al (2022)50 | Atezolizumab | |||
Gray: no effect. Green: positive effect. Red: negative effect.
ADA, antidrug antibody; NA, not applicable; PK, pharmacokinetics.